skip to Main Content

Italy In-Vitro Diagnostics Market Size, Share & Growth Report 2030

Renub Research has recently published a report named “Italy In-Vitro Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028,” providing a detailed industry analysis that consists of market share insights. Furthermore, In addition, the report comprises competitor and regional research and contemporary extension in the Italy In-Vitro Diagnostics (IVD) Market.

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures:

Italy’s In-Vitro Diagnostics Market shall grow at a CAGR of 6.65% during the 2022-2028. In-Vitro Diagnostics (IVD) refers to medical devices, reagents, and systems used for diagnostic testing outside the human body. It plays a crucial role in healthcare by detecting and diagnosing diseases, monitoring treatment response, and assessing overall health.

The Italy market for in-vitro diagnostics (IVD) is facing escalating challenges. Italy is experiencing a surge in the prevalence of diverse diseases, encompassing cancer, autoimmune diseases, myocardial infarctions, arrhythmia, and inflammatory conditions. This escalating trend in disease incidence is projected to propel the demand for IVD testing in the country. Breast cancer, prostate cancer, colorectal cancer, lung cancer, and bladder cancer rank among the most frequently diagnosed cancers in Italy. Additionally, as per the International Diabetes Federation, Italy had an estimated 4.4 million cases of diabetes in its adult population in 2022.

Unhealthy dietary habits, high tobacco and alcohol consumption, obesity, and sedentary lifestyles contribute to the mounting prevalence of these targeted diseases in Italy. Furthermore, alterations in regulatory policies are expected to fuel the growth of the IVD market in the forthcoming years. In September 2022, the Italy government revised its national regulatory framework concerning IVD products, with the aim of enhancing the safety standards of such products within the country. These policy changes are anticipated to ensure a higher level of safety for IVD products available in Italy.

According to the 2023 report by Renub Research, individuals who are 65 years and older account for over 24 Percent of Italy’s total population. Furthermore, the report reveals that more than 23.5 million people in Italy are affected by at least one chronic disease, and a considerable portion of them suffer from two or more chronic conditions.

However, stringent regulations and reimbursement policies in the Italy in-vitro diagnostics (IVD) market pose challenges to the widespread adoption and accessibility of advanced diagnostic technologies.

The services segment will continue thriving in the Italy in-vitro diagnostics (IVD) market. 

The continuous expansion of services in the in-vitro diagnostics (IVD) market in Italy can be attributed to various factors. One key driver is the increasing demand for specialized and personalized diagnostic services, fuelled by the growing prevalence of chronic diseases and the need for targeted treatment approaches. Technological advancements have played a crucial role in enhancing the capabilities and scope of diagnostic services, offering more accurate and comprehensive testing options. The emphasis on preventive and personalized healthcare has also led to a rising demand for screening and monitoring services. Additionally, the aging population has contributed to the growth of services in the IVD market, necessitating the provision of geriatric healthcare services. The integration of digital technologies and telemedicine has further improved the accessibility of diagnostic services, enabling remote consultations and faster results delivery. Moreover, favourable government policies and reimbursement frameworks have incentivized the utilization of services, supporting the overall growth of the market.

Products–the Italy in-vitro diagnostics (IVD) Market breakup from 3 Viewpoints:

  1. Services
  2. Instruments
  3. Reagents

PCR tests shall maintain their dominant market share in the Italy in-vitro diagnostics market.

PCR (Polymerase Chain Reaction) is widely recognized for its exceptional sensitivity and specificity in detecting pathogens and genetic material. Its accuracy and reliability make it a preferred choice in various fields such as genetics, forensics, and infectious disease diagnosis. PCR tests can be rapidly scaled up, providing quick results and offering flexibility across different testing platforms. With a robust track record of diagnostic validity and regulatory approval, PCR tests inspire confidence among healthcare providers. Furthermore, the COVID-19 pandemic has played a significant role in accelerating the widespread adoption of PCR tests, solidifying their substantial market share in the in-vitro diagnostics market in Italy.

Test types – the Italy in-vitro diagnostics Market breakup from 11 Viewpoints:

  2. PCR
  3. Rapid Test
  4. Fluorescence Immunoassays (FIA)
  5. In Situ Hybridization
  6. Transcription Mediated Amplification
  7. Sequencing
  8. Colorimetric Immunoassay
  9. Radioimmunoassay (RIA)
  10. Isothermal Nucleic Acid Amplification Technology
  11. Others

The application of the Italy in-vitro diagnostics market in infectious diseases is experiencing rapid growth.

Italy susceptibility to the transmission of infectious diseases has been heightened by global travel, migration, and changing demographics. The emergence of antimicrobial resistance further underscores the critical role of accurate diagnostics in effective treatment. Outbreaks and epidemics, including influenza, measles, and COVID-19, have created a higher demand for rapid and precise diagnostics to enable timely intervention. Increased awareness and proactive screening initiatives have also played a role in driving market growth. Moreover, advancements in molecular diagnostics and the availability of rapid point-of-care testing have enhanced the accuracy and capabilities of infectious disease diagnostics, contributing to the expansion of the in-vitro diagnostics (IVD) market in Italy.

Application – the Italy in-vitro diagnostics (IVD) Market breakup from 8 Viewpoints:

  1. Infectious Diseases
  2. Diabetes
  3. Cardiology
  4. Oncology
  5. Nephrology
  6. Autoimmune Diseases
  7. Drug Testing
  8. Others

The forecast period anticipates a profitable growth of Molecular Diagnostics/Genetics in the Italy in-vitro diagnostics  market.

Italy in-vitro diagnostics (IVD) market is poised for profitable growth, particularly in the field of Molecular Diagnostics/Genetics. The forecast period anticipates significant advancements and increased adoption of molecular diagnostic techniques in Italy. This growth can be attributed to the rising demand for personalized medicine, the increasing prevalence of chronic diseases, and the expanding applications of molecular diagnostics in disease diagnosis, monitoring, and treatment. These factors are expected to drive market expansion and present lucrative opportunities for stakeholders in the Italian IVD market.

Request a free sample copy of the report:

Technology – the Italy in-vitro diagnostics (IVD) Market breakup from 7 Viewpoints:

  1. Immunoassay
  2. Clinical Chemistry
  3. Molecular Diagnostics/Genetics
  4. Hematology
  5. Microbiology
  6. Coagulation
  7. Others

Hospitals maintain a dominant position in the Italy in-vitro diagnostics market.

Hospitals play a leading role in the Italy in-vitro diagnostics (IVD) market, leveraging their extensive healthcare services and seamless integration of diagnostics with various specialties. With well-established infrastructure, abundant resources, and skilled personnel, hospitals are well-equipped to provide comprehensive IVD operations. As primary care providers and referral centers, hospitals offer various medical services, facilitating accurate diagnosis and interpretation of IVD test results. Furthermore, hospitals benefit from favourable reimbursement and funding mechanisms, ensuring adherence to rigorous regulatory standards for patient safety and test accuracy.

End-User – the Italy in-vitro diagnostics (IVD) Market breakup from 4 Viewpoints:

  1. Hospitals
  2. Laboratories
  3. Home – Care
  4. Others

Competitive Landscape.

Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, and Sysmex Corporation are among the prominent companies in the Italy in-vitro diagnostics market.

Company have been covered from 3 Viewpoints:

1.    Overview
2.    Recent Development
3.    Revenue

Company Analysis:

  1. Roche Diagnostics
  2. Abbott Diagnostics
  3. Siemens Healthineers
  4. Danaher Corporation
  5. Thermo Fisher Scientific
  6. Sysmex Corporation

Related Reports

France In-Vitro Diagnostics Market, Size, Forecast 

Japan In-Vitro Diagnostics (IVD) Market, Size, Forecast

Saudi Arabia In Vitro Diagnostics Market, Forecast

Europe In-Vitro Diagnostics Market, Size, Forecast 

Germany In-Vitro Diagnostics Market, Size, Forecast


About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.


Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)




This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top